

SPRING GROUP MEETING

Seattle

Melanoma Committee

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Michael Wu, PhD
 James Moon, MS
 Shay Bellasea, MS

Scientific Leadership

Translational Medicine: William E. Carson, III, MD
 Radiation Oncology: Evan J. Wuthrick, MD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: Clara Curiel-Lewandrowski, MD
 Imaging: Ari M. VanderWalde, MD
 Medical Oncology: Sapna Pradyuman Patel, MD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: Jeffrey A. Sosman, MD
 SWOG's ECOG Liaisons: Thach-Giao Truong, MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Andrew Poklepovic, MD
 Digital Engagement: Zeynep Eroglu, MD

Designates

Cancer Control Liaison: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Data Coordinator: Matt Gospe, BS
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRA: Kathryn Allen, BA, CCRP
 Nurse: Lisa S. Morgan, RN, OCN
 Patient Advocate: Samantha Guild, J.D.
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, April 4, 2024 10:00 a.m. - 12:00 p.m.

Room: Virtual Only

Agenda

Targeting RAScals in solid tumor oncology, David Hong, MD, The University of Texas MD Anderson Cancer Center

Active Studies

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Temporarily Closed to Accrual as of 04/07/2023

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015.

CTSU/EA6192. "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020.

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023

Closed Studies

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced

Melanoma Committee

Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent.” Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, “A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma.” Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, “DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial.” SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPH Activated: 02/18/2020. Closed: 09/23/2022.

ECOG Liaison Updates

Patient Advocate Updates

Publications

The publications listed below were received by the Group Chair’s Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1221 A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers. Algazi AP, Moon J, Lao C, Chmielowski B, Kendra K, Lewis K, Gonzalez R, Kim K, Godwin JE, Curti B, Latkovic-Taber M, Lomeli S, Gufford B, Scumpia P, Lo R, Othus M, Ribas A. *Cancer* Jan 23. doi: 10.1002/cncr.35200. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38261444/>

Submitted Manuscripts

S1801 Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801). Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. Submitted, 2024.

Melanoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S2000	S2015	A091903	EA6141	EA6174	EA6192	EA6194
Banner MD Anderson Cancer Center	-	6	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	16	-	-
Cancer Research Consortium of West Michigan NCORP	-	60	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	15	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	3	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	9	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	1	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	4	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	3	-	-	-	-	-
Intermountain Medical Center	-	7	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	26	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	9	-	-	-	-	-
Moffitt Cancer Center	16	33	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-	-
Northwell Health NCORP	-	2	-	-	-	-	-
Northwestern University LAPS	-	21	-	1	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	1	20	-	-	3	3	-
SCL Health Saint Joseph Hospital	-	-	-	-	1	-	-
Sutter Cancer Research Consortium	-	-	-	6	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	5	-	4	8	-	1
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	3	-	-
University of Arkansas for Medical Sciences	-	3	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	4	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	30	-	-	1	-	-
University of Kentucky/Markey Cancer Center	-	3	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	7	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	-	-	-	-
University of Rochester LAPS	-	3	-	3	1	-	-
University of Texas Health Science Center at San Antonio	-	1	-	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	11	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	20	-	-	8	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	6	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	16	-	8	1	-	-
ALLIANCE	1	37	-	-	-	-	-
ECOG-ACRIN	4	95	-	-	-	-	-
NRG	1	41	-	-	-	-	-
Total	29	468	1	58	53	8	1

